Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) was up 5.9% on Thursday . The stock traded as high as $25.87 and last traded at $25.87. Approximately 2,789 shares were traded during trading, a decline of 95% from the average daily volume of 60,452 shares. The stock had previously closed at $24.43.
Analyst Upgrades and Downgrades
Separately, JPMorgan Chase & Co. assumed coverage on Ascentage Pharma Group International in a research report on Thursday, March 27th. They set an "overweight" rating on the stock.
Read Our Latest Stock Report on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Up 3.4%
The stock's 50-day simple moving average is $22.70.
Hedge Funds Weigh In On Ascentage Pharma Group International
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new stake in shares of Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International at the end of the most recent quarter.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Further Reading
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
